February 5, 2026 Applicants with casirivimab-imdevimab are introduced and consulted to our private hospitals from Follow-up Center in Osaka prefecture
October 25, 2024 According to the last mentioned reports, decreased INPP4B continues to be observed predominantly in basal-like breasts carcinoma and is apparently connected with unfavorable individual final result [10], [43]
September 24, 2024 Excluded from your systematic evaluate (but not from your framing narrative critiques) were case reports, reviews and meta-analyses
May 2, 2023 This case highlights a unique presentation of nummular dermatitis in an individual with recalcitrant palmoplantar psoriasis on guselkumab
March 23, 2023 The data sets generated and/or analyzed during the current study are available from the corresponding author on reasonable request
March 4, 2023 designed the research, analyzed and interpreted the data, and published the manuscript; K
December 12, 2022 In Per protocol (PP) analysis, the rate of eradication in the TT and ST groups was 87